Business Context and Reporting Period
This Form 8-K filing by Angion Biomedica Corp. (ANGN) reports on the results of the 2022 Annual Meeting of Stockholders held on June 9, 2022. The filing details the voting outcomes for the election of directors and the ratification of the independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes
No material financial changes are reported in this filing. The document serves as a disclosure of shareholder voting outcomes rather than a financial performance update.
Guidance, Outlook, and Management Commentary
There is no guidance, outlook, or management commentary regarding future financial performance in this filing. The document notes that a more complete description of the matters voted upon is available in the proxy statement filed on April 27, 2022.
Important Facts for Investors to Verify
- Director Election Results: Both proposed directors, Jay R. Venkatesan, M.D., and Karen J. Wilson, were elected. Significant broker non-votes were recorded (5,689,515 for each candidate).
- Accounting Firm Ratification: Shareholders ratified the appointment of Moss Adams LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Voting Tally: For the accounting firm ratification, 20,658,864 votes were cast "For," with only 527 "Against" and 371 "Abstain."
- Company Name Discrepancy: The request metadata lists "Elicio Therapeutics, Inc.," but the filing content explicitly identifies the registrant as "Angion Biomedica Corp." Investors should verify the correct entity.